Saroja Pharma Industries India Ltd Financials
Company Logo

Saroja Pharma Industries India Ltd Financial Statement

Saroja Pharma Industries India Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

No Data Available

Saroja Pharma Industries India Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual40.67
Operating Expenses Annual38.12
Operating Profit Annual2.75
Interest Annual1.45
Depreciation0.09
Net Profit Annual0.88
Tax Annual0.33

Saroja Pharma Industries India Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning0.36
Cash Flow from Operations1.02
Cash Flow from Investing-4.76
Cash Flow from Financing3.70
Cash Flow at the End0.32

Saroja Pharma Industries India Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)6.76
PBIT Margin (%)6.54
PBT Margin (%)2.04
Net PROFIT Margin (%)2.16
Return On Networth / Equity (%)8.92
Return On Networth /Employed (%)14.92
Return On Assets (%)4.93
Total Debt / Equity (X)0.81
Asset Turnover Ratio (%)2.28

Saroja Pharma Industries India Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual2.51
Total Current Assets Annual17.60
Non Current Assets Annual8.96
Total Shareholders Funds Annual14.64
Total Assets Annual26.56

Saroja Pharma Industries India Ltd Earning Calls

No Data Availabe

Get Your FAQs Right

As of Nov 5, 2024, Saroja Pharma Industries India Ltd has a market capitalization of 14.11 Cr. Value Research classifies it as a Micro-Cap company.
Yes, Saroja Pharma Industries India Ltd is debt-free with a debt-to-equity ratio of 0.39.
In FY 2023 , Saroja Pharma Industries India Ltd recorded a total revenue of approximately 40.67 Cr marking a significant milestone in the company's financial performance.
Saroja Pharma Industries India Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately Infinity% and -0.2% annually, respectively..
Saroja Pharma Industries India Ltd's current PE ratio is 16.03.
Saroja Pharma Industries India Ltd's ROCE averaged 18.3% from the FY ending March 2022 to 2024, with a median of 18.4%. It peaked at 23.4% in March 2022, reflecting strong capital efficiency over the period..
Saroja Pharma Industries India Ltd's latest EBIT is Rs. 2.66 Cr, surpassing the average EBIT of Rs. 2.62 Cr over the 5 years..